Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Receivables (2016 - 2025)

ImmunityBio (IBRX) has disclosed Receivables for 7 consecutive years, with $42.6 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 1564.73% to $42.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $42.6 million through Dec 2025, up 1564.73% year-over-year, with the annual reading at $42.6 million for FY2025, 1564.73% up from the prior year.
  • Receivables for Q4 2025 was $42.6 million at ImmunityBio, up from $32.0 million in the prior quarter.
  • The five-year high for Receivables was $42.6 million in Q4 2025, with the low at $2.0 million in Q4 2023.
  • Average Receivables over 4 years is $11.5 million, with a median of $3.3 million recorded in 2023.
  • The sharpest move saw Receivables crashed 38.05% in 2024, then surged 1564.73% in 2025.
  • Over 4 years, Receivables stood at $3.2 million in 2022, then plummeted by 36.71% to $2.0 million in 2023, then increased by 26.8% to $2.6 million in 2024, then soared by 1564.73% to $42.6 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $42.6 million, $32.0 million, and $22.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.